As of 2025-07-05, the Intrinsic Value of Voyager Therapeutics Inc (VYGR) is (17.02) USD. This VYGR valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 3.20 USD, the upside of Voyager Therapeutics Inc is -631.9%.

The range of the Intrinsic Value is (156.84) - (8.69) USD.

Is VYGR undervalued or overvalued?

Based on its market price of 3.20 USD and our intrinsic valuation, Voyager Therapeutics Inc (VYGR) is overvalued by 631.9%.

Note: result may not be accurate due to the invalid valuation result of DCF model.

3.20 USD

Stock Price

(17.02) USD

Intrinsic Value

Intrinsic Value Details

VYGR Intrinsic Value - Valuation Summary

	Range	Selected	Upside
a
DCF (Growth Exit 5Y)	(156.84) - (8.69)	(17.02)	-631.9%
Peter Lynch Fair Value	-38.26 - -38.26	-38.26	-1295.63%
P/E Multiples	(20.97) - (20.05)	(21.50)	-771.9%
EV/EBITDA Multiples	(18.74) - (19.34)	(17.68)	-652.5%
Earnings Power Value	0.59 - 0.85	0.72	-77.6%

VYGR Intrinsic Value - Peers Comparison

	Range	Selected	Upside
a
Abbvie Inc	59.01 - 369.54	115.21	-39.1%
Amgen Inc	184.69 - 828.17	326.99	9.6%
Gilead Sciences Inc	17.78 - 97.79	34.67	-69.0%
Regeneron Pharmaceuticals Inc	437.98 - 999.89	599.19	9.5%
CytomX Therapeutics Inc	2.81 - 5.31	3.60	44.2%
Rigel Pharmaceuticals Inc	21.22 - 74.08	32.70	72.7%
ImmuCell Corp	(0.43) - 4.59	0.16	-97.5%
Medicure Inc	0.62 - 0.63	0.62	-50.2%

VYGR Intrinsic Value - Key Valuation Metrics

Market Cap (mil)	177
Beta	1.41
Outstanding shares (mil)	55
Enterprise Value (mil)	102

Market risk premium	5.1%
Cost of Equity	8.25%
Cost of Debt	5%
WACC	6.0%